logo
Share SHARE
FONT-SIZE Plus   Neg

Eli Lilly Says Phase III Study Of Cialis Meets Primary Endpoint - Quick Facts

Eli Lilly & Co (LLY) Tuesday announced that a Phase III study showed both Cialis and tamsulosin significantly improved scores on the International Prostate Symptom Score, compared to placebo, in men with signs and symptoms suggestive of benign prostatic hyperplasia, or BPH.

The randomized, double-blind, placebo-controlled, parallel-group, 12-week trial, conducted in 44 urology centers in 10 countries, assessed the efficacy and safety of Cialis 5 mg for daily use in parallel with tamsulosin 0.4 mg in men aged 45 years and older with signs and symptoms of BPH.

The company stated that Cialis improved erectile dysfunction in those men who had both signs and symptoms of BPH and ED.

The study also showed that maximum urinary flow rate increased significantly versus placebo with both Cialis and tamsulosin.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Microsoft is reportedly working on streaming PC games to Xbox One consoles as the software giant strives to generate demand for both. French oil and gas giant Total SA (TTA.L, TTFNF.PK, TOT) reported Wednesday a profit for the second quarter that declined four percent from last year, reflecting a sales decline amid sharply lower oil prices. However, hydrocarbon production grew 12 percent from last year. The company's results were... Procter & Gamble Co., (PG) Tuesday announced the promotion of David Taylor to the role of Chief Executive Officer, as the consumer goods giant replaces Chief Executive A.G. Lafley for the second time. David Taylor, a 35-year-veteran and currently Group President of Global Beauty, Grooming and Health...
comments powered by Disqus
RELATED NEWS
Trade LLY now with 
Follow RTT